en

PRODUCT DETAIL

Skyrizi 75 mg injekčný roztok v naplnenej injekčnej striekačke

Code 1347D
MA number EU/1/19/1361/001
Product Form: sol inj 2x0,83 ml/75 mg (striek.inj.napl.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
Therapeutic Class: 59 - IMMUNOPRAEPARATA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 Immunosuppressants
L04A Immunosuppressants
L04AC Interleukin inhibitors
L04AC18 Risankizumab
Shelf life: 24
Route of admin.: Subcutaneous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 26.04.2019
Validity: 26.04.2024
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 03.06.2021
eu-flag.png sk-flag.png